nach oben

Erschienen in:

06.03.2023 | Gallenblasenkarzinom | CME-Topic

Personalisierte Therapie biliärer Karzinome

verfasst von: Sabrina Welland, Clara Weigle, PD Dr. Kai Timrott, PD Dr. Oliver Beetz, PD Dr. Anna Saborowski, Prof. Dr. Arndt Vogel

Erschienen in: best practice onkologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Biliäre Tumoren sind eine heterogene Gruppe von Tumorerkrankungen, für die sehr lange nur eine sehr begrenzte Anzahl von Therapiemöglichkeiten in der fortgeschrittenen Situation zur Verfügung stand. Neben interventionell radiologischen Verfahren hat sich auch das Spektrum der verfügbaren Systemtherapien deutlich erweitert. Dabei eröffnet vor allem die verbesserte molekulare Charakterisierung der Tumoren durch Hochdurchsatzsequenzierung neue therapeutische Angriffspunkte, wodurch eine Individualisierung der Therapie mit einer deutlichen Verbesserung der Prognose möglich wird.

Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet 397(10272):428–444CrossRefPubMed

Ghouri YA, Mian I, Blechacz B (2015) Cancer review: cholangiocarcinoma. J Carcinog 14:1. https://doi.org/10.4103/1477-3163.151940CrossRefPubMedPubMedCentral

Filmann N, Walter D, Schadde E, Bruns C, Keck T, Lang H et al (2019) Mortality after liver surgery in Germany. Br J Surg 106(11):1523–1529CrossRefPubMed

Bird N, Elmasry M, Jones R, Elniel M, Kelly M, Palmer D et al (2017) Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma. Br J Surg 104(4):418–425CrossRefPubMed

Iacono C, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A (2013) Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg 257(2):191–204CrossRefPubMed

Mehrabi A, Khajeh E, Ghamarnejad O, Nikdad M, Chang DH, Büchler MW et al (2020) Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma. Eur J Radiol 125:108897CrossRefPubMed

Lang H, Baumgart J, Mittler J (2020) Associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) registry: what have we learned? Gut Liver 14(6):699–706CrossRefPubMedPubMedCentral

Ma WJ, Wu ZR, Shrestha A, Yang Q, Hu HJ, Wang JK et al (2018) Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma. Hepatobiliary Surg Nutr 7(4):251–269CrossRefPubMedPubMedCentral

Li B, Song JL, Aierken Y, Chen Y, Zheng JL, Yang JY (2018) Nonanatomic resection is not inferior to anatomic resection for primary intrahepatic cholangiocarcinoma: a propensity score analysis. Sci Rep 8(1):17799–17795CrossRefPubMedPubMedCentral

10.

Si A, Li J, Yang Z, Xia Y, Yang T, Lei Z et al (2019) Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with Intrahepatic cholangiocarcinoma. Ann Surg Oncol 26(6):1841–1850CrossRefPubMed

11.

Lim JH, Choi GH, Choi SH, Kim KS, Choi JS, Lee WJ (2013) Liver resection for Bismuth type I and Type II hilar cholangiocarcinoma. World J Surg 37(4):829–837CrossRefPubMed

12.

Matsuyama R, Mori R, Ota Y, Homma Y, Kumamoto T, Takeda K et al (2016) Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction. Ann Surg Oncol 23(Suppl 4):475–484CrossRefPubMed

13.

Lee HG, Lee SH, Yoo DD, Paik KY, Heo JS, Choi SH et al (2009) Carcinoma of the middle bile duct: is bile duct segmental resection appropriate? World J Gastroenterol 15(47):5966–5971CrossRefPubMedPubMedCentral

14.

Schreuder AM, Engelsman AF, van Roessel S, Verheij J, Besselink MG, van Gulik TM et al (2019) Treatment of mid-bile duct carcinoma: local resection or pancreatoduodenectomy? Eur J Surg Oncol 45(11):2180–2187CrossRefPubMed

15.

Haber PK, Wabitsch S, Kästner A, Andreou A, Krenzien F, Schöning W et al (2020) Laparoscopic liver resection for Intrahepatic cholangiocarcinoma: a single-center experience. J Laparoendosc Adv Surg Tech A 30(12):1354–1359CrossRefPubMed

16.

Guerrini GP, Esposito G, Tarantino G, Serra V, Olivieri T, Catellani B et al (2020) Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: the first meta-analysis. Langenbecks Arch Surg 405(3):265–275CrossRefPubMed

17.

Levi Sandri GB, Spoletini G, Mascianà G, Colasanti M, Lepiane P, Vennarecci G et al (2017) The role of minimally invasive surgery in the treatment of cholangiocarcinoma. Eur J Surg Oncol 43(9):1617–1621CrossRefPubMed

18.

Beetz O, Timrott A, Weigle CA, Schroeter A, Cammann S, Klempnauer J et al (2021) Proposal of a new definition of “very early” Intrahepatic cholangiocarcinoma—a retrospective single-center analysis. J Clin Med 10(18):4073. https://doi.org/10.3390/jcm10184073CrossRefPubMedPubMedCentral

19.

Bartsch F, Paschold M, Baumgart J, Hoppe-Lotichius M, Heinrich S, Lang H (2019) Surgical resection for recurrent Intrahepatic cholangiocarcinoma. World J Surg 43(4):1105–1116CrossRefPubMed

20.

Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S et al (2018) A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 45(10):1731–1741CrossRefPubMed

21.

Ray CE Jr, Edwards A, Smith MT, Leong S, Kondo K, Gipson M et al (2013) Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 24(8):1218–1226CrossRefPubMed

22.

Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB et al (2008) Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 12(1):129–137CrossRefPubMed

23.

Moole H, Tathireddy H, Dharmapuri S, Moole V, Boddireddy R, Yedama P et al (2017) Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: a systematic review and meta-analysis. World J Gastroenterol 23(7):1278–1288CrossRefPubMedPubMedCentral

24.

Yang J, Wang J, Zhou H, Zhou Y, Wang Y, Jin H et al (2018) Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 50(8):751–760CrossRefPubMed

25.

Lee J, Yoon WS, Koom WS, Rim CH (2019) Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 195(2):93–102CrossRefPubMed

26.

Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663–673CrossRefPubMed

27.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMed

28.

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469–474CrossRefPubMedPubMedCentral

29.

Shroff RT, Guthrie KA, Scott AJ et al (2023) SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol 41(4_suppl):LBA490-LBA

30.

Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P et al (2022) Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study. J Clin Oncol 40(3):262–271CrossRefPubMed

31.

Do-Youn Aiwu ORH, Shukui Q, Li-Tzong CTO, Arndt V et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1(8):EVIDoa2200015

32.

Bang Y, Doi T, Braud F, Piha-Paul S, Hollebecque A, Razak AA et al (2015) 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028

33.

Bang Y, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK et al (2019) Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. JCO Clin Cancer Inform 37(15):4079

34.

Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22(5):690–701CrossRefPubMedPubMedCentral

35.

Yoo C, Kim K, Jeong JH, Kim I, Kang MJ, Cheon J et al (2021) Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 22(11):1560–1572CrossRefPubMed

36.

Vogel A, Wenzel P, Folprecht G, Schütt G, Wege H, Kretzschmar A et al (2022) Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies. Ann Oncol 33:S19–S26. https://doi.org/10.1016/annonc/annonc1036CrossRef

37.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7(6):586–595CrossRefPubMed

38.

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6):796–807CrossRefPubMedPubMedCentral

Titel: Personalisierte Therapie biliärer Karzinome
verfasst von: Sabrina Welland
Clara Weigle
PD Dr. Kai Timrott
PD Dr. Oliver Beetz
PD Dr. Anna Saborowski
Prof. Dr. Arndt Vogel
Publikationsdatum: 06.03.2023
Verlag: Springer Medizin
Schlagwörter: Gallenblasenkarzinom
Primär biliäre Cholangitis
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Biomarker
Erschienen in: best practice onkologie / Ausgabe 3/2023
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-023-00463-2

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Digitale Anwendungen in der Onkologie: Kann ein Klick den Arztbesuch ersetzen?

58/m mit schmerzloser Lymphknotenschwellung, Nachtschweiß und Fieber

Welche Versicherungen sich lohnen – und welche nicht

Therapeutische Strategie bei hepatozellulärem Karzinom

Wichtige Studien vom ASH 2022

Editorial